Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raynaud's phenomenon.

E V Lally1

  • 1Brown University School of Medicine, Providence, Rhode Island.

Current Opinion in Rheumatology
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Raynaud's phenomenon affects 5% of adults. Classifying it as primary or secondary helps understand its causes and guides treatment, with new drugs showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment-resistant diffuse calcinosis in scleroderma.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.

Annals of the rheumatic diseases·2006
Same author

Relapse of polymyositis after prolonged remission.

The Journal of rheumatology·1997
Same author

Septic sacroiliitis.

Seminars in arthritis and rheumatism·1996
Same author

Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma.

Arthritis and rheumatism·1995
Same author

Advances in the medical management of chronic arthritis.

Rhode Island medicine·1994
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Area of Science:

  • Vascular Medicine
  • Rheumatology
  • Immunology

Background:

  • Raynaud's phenomenon affects approximately 5% of the adult population, often without medical consultation.
  • Classification into primary and secondary forms is crucial for understanding pathophysiology and guiding treatment strategies.
  • Occupation-related Raynaud's phenomenon is a significant cause of economic loss.

Purpose of the Study:

  • To review the classification, pathophysiology, and emerging treatments for Raynaud's phenomenon.
  • To highlight diagnostic approaches for differentiating primary and secondary Raynaud's.
  • To discuss the prognostic value of specific diagnostic tests.

Main Methods:

  • Review of current literature on Raynaud's phenomenon epidemiology, classification, and pathophysiology.

Related Experiment Videos

  • Discussion of diagnostic tools including nailfold capillary microscopy and autoantibody analysis.
  • Overview of current and emerging therapeutic agents.

    • Main Results:

    • Primary Raynaud's hypotheses include neurogenic and local fault mechanisms.
    • Secondary Raynaud's research focuses on obliterative arteriopathy and endothelial factors.
    • Nailfold capillary microscopy and autoantibody analysis can predict evolution from primary to secondary Raynaud's, particularly for systemic sclerosis.

    Conclusions:

    • Accurate classification of Raynaud's phenomenon is essential for patient management.
    • Diagnostic markers can identify patients at risk for developing secondary Raynaud's.
    • Novel vasodilating and antithrombotic agents offer potential therapeutic benefits for all forms of Raynaud's phenomenon.